Non-conventional therapies for Peyronie’s disease: what is the evidence for efficacy?

Ishan Aditya, Jethro C. C. Kwong, Yonah Krakowsky, Ethan D. Grober


Background: In recent years, there has been a surge in non-conventional therapies for Peyronie’s disease (PD). With increasing interest in these novel therapies, we conducted a narrative review to explore the efficacy and safety of these treatments to provide clarity for patients and providers.
Methods: A literature search was conducted to find studies describing non-conventional treatments of PD. These treatments were defined as those within the standard of care, including intralesional therapies and surgical options.
Results: A total of 14 studies were found. Non-conventional therapies included platelet-rich plasma (PRP), hyaluronic acid (HA), combination therapy of PRP and HA, extracorporeal shockwave therapy (ESWT), stem cell therapy (SCT), mycophenolate mofetil (MMF), and H-100. Most studies were limited to animal models and reported modest improvements in angulation and erectile function. Complication rates and cost of each treatment were infrequently reported.
Conclusions: There is limited evidence supporting non-conventional therapies for PD. As such, they are currently not recommended in clinical guidelines.